Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 4/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827758 | 1.00 | CA1 (0.61) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL122044 | 1.00 | CA1 (0.61) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL10866301 | 0.98 | CA1 (0.59) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL12326336 | 0.98 | CA1 (0.59) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL7712209 | 0.98 | CA1 (0.59) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL23857835 | 0.98 | CA1 (0.59) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL5423239 | 0.98 | CA1 (0.59) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL277898 | 0.98 | CA1 (0.59) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL2348891 | 0.98 | CA1 (0.59) | CA1CA2ACE2EPHX1TP53 | |
| SCHEMBL13854594 | 0.98 | CA1 (0.59) | CA1CA2ACE2EPHX1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493402-B2 | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-11-15 | — | — | US | claimed |
| EP-1430020-B1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2016-03-02 | — | — | EP | claimed |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | Dompé S.p.A. (IT) | 2013-03-28 | — | — | US | claimed |
| US-8288368-B2 | inhibitors of the C5a induced chemotaxis; psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion | DOMPÉ PHA.R.MA S.P.A. (IT) | 2012-10-16 | — | — | US | claimed |
| JP-4267922-B2 | — | — | 2009-05-27 | — | — | JP | claimed |
| EP-1856031-B1 | 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-02-25 | — | — | EP | claimed |
| US-20080312293-A1 | 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them | DOMPE' PHA.R.MA.S.P.A. (IT) | 2008-12-18 | — | — | US | claimed |
| WO-2008110351-A2 | USE OF (R) AND (S)-2-ARYL-PROPIONIC ACID DERIVATIVES AS ANTISEPTIC AGENTS | DOMPE' PHA.R.MA S.P.A. (IT) | 2008-09-18 | — | — | WO | claimed |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPE PHA.R.MA S.P.A. (IT) | 2008-02-21 | — | — | US | claimed |
| EP-1856031-A1 | 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2007-11-21 | — | — | EP | claimed |
| WO-2006063999-A1 | 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA.S.P.A. (IT) | 2006-06-22 | — | — | WO | claimed |
| US-7026510-B2 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | Dompé S.p.A. (IT) | 2006-04-11 | — | — | US | claimed |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPE S.P A. (IT) | 2005-04-14 | — | — | US | claimed |
| US-20040266870-A1 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-12-30 | — | — | US | claimed |
| JP-2004525112-A | — | — | 2004-08-19 | — | — | JP | claimed |
| EP-1430020-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-06-23 | — | — | EP | claimed |
| EP-1366018-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.P.A. (IT) | 2003-12-03 | — | — | EP | claimed |
| WO-2003029187-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-04-10 | — | — | WO | claimed |
| WO-2002068377-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.p.A. (IT) | 2002-09-06 | — | — | WO | claimed |
| EP-0330529-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2-ARYL-PROPIONIC ACIDS | RHONE-POULENC SANTE (FR) | 1993-03-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266870-A1 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | C3AR1, IL5, AP1G1 | CA1 4269/4885CA2 2368/4885ACE2 1687/4885 |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | C5AR2, C3AR1, C5AR1 | CA1 4444/4885CA2 3841/4885ACE2 940/4885 |
| US-20080312293-A1 | 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR2, C5AR1 | CA1 3484/4885CA2 3116/4885ACE2 734/4885 |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | C5AR2, C3AR1, C5AR1 | CA1 4761/4885CA2 3586/4885ACE2 844/4885 |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | C5AR2, C3AR1, C5AR1 | CA1 4466/4885CA2 3893/4885ACE2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.